Article
Colony-stimulating factors improve neoadjuvant immunochemotherapy efficacy in non-small-cell lung cancer without EGFR or ALK mutations: A double-center real-world retrospective study.
Lung cancer (Amsterdam, Netherlands) - 1 May 2026
Huang Yan, Lin Xirui, Li Zhichao, Fang Caiyan, Chen Jiyang, Xie Xiuying, Wu Hansheng, Wang Weidong, Yang Hong, Fu Jianhua
Abstract excerpt
BACKGROUND: Preclinical evidence suggests colony-stimulating factors (CSFs) may modulate antitumor immunity. This study evaluated granulocyte colony-stimulating factor (G-CSF) administration on neoadjuvant immunochemotherapy (NICT) efficacy in non-small-cell lung cancer (NSCLC) without EGFR or ALK mutations. METHODS: In this double-center retrospective study (2019-2025), 439 stage II/III NSCLC patients without...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.